Harvest Investment Services LLC cut its holdings in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 26.4% during the third quarter, HoldingsChannel.com reports. The firm owned 2,284 shares of the medical equipment provider’s stock after selling 819 shares during the period. Harvest Investment Services LLC’s holdings in ABIOMED were worth $388,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. FMR LLC raised its position in ABIOMED by 287.2% during the 1st quarter. FMR LLC now owns 30,927 shares of the medical equipment provider’s stock valued at $8,833,000 after purchasing an additional 22,940 shares during the last quarter. Crossmark Global Holdings Inc. raised its position in ABIOMED by 3.3% during the 2nd quarter. Crossmark Global Holdings Inc. now owns 3,242 shares of the medical equipment provider’s stock valued at $845,000 after purchasing an additional 104 shares during the last quarter. EFG Asset Management Americas Corp. raised its position in ABIOMED by 9.6% during the 2nd quarter. EFG Asset Management Americas Corp. now owns 10,036 shares of the medical equipment provider’s stock valued at $2,614,000 after purchasing an additional 880 shares during the last quarter. Retirement Systems of Alabama raised its position in ABIOMED by 7.1% during the 2nd quarter. Retirement Systems of Alabama now owns 95,998 shares of the medical equipment provider’s stock valued at $25,007,000 after purchasing an additional 6,375 shares during the last quarter. Finally, Scout Investments Inc. raised its position in ABIOMED by 94.5% during the 2nd quarter. Scout Investments Inc. now owns 227,247 shares of the medical equipment provider’s stock valued at $59,196,000 after purchasing an additional 110,435 shares during the last quarter. 90.91% of the stock is currently owned by institutional investors and hedge funds.

A number of research analysts have commented on the company. ValuEngine raised ABIOMED from a “sell” rating to a “hold” rating in a research report on Wednesday, September 4th. Leerink Swann upped their price target on ABIOMED from $195.00 to $240.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. William Blair reissued a “buy” rating on shares of ABIOMED in a research report on Monday, September 30th. Raymond James lowered ABIOMED from an “outperform” rating to a “market perform” rating in a research report on Tuesday, October 29th. Finally, BidaskClub raised ABIOMED from a “sell” rating to a “hold” rating in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $301.20.

Shares of NASDAQ:ABMD traded up $1.91 during trading on Thursday, hitting $221.92. The stock had a trading volume of 10,919 shares, compared to its average volume of 702,512. ABIOMED, Inc. has a 12 month low of $155.02 and a 12 month high of $364.31. The company has a market capitalization of $9.94 billion, a PE ratio of 61.65, a PEG ratio of 1.92 and a beta of 0.37. The firm’s fifty day moving average is $185.81 and its 200 day moving average is $225.09.

ABIOMED (NASDAQ:ABMD) last announced its earnings results on Thursday, October 31st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.93 by $0.10. ABIOMED had a return on equity of 19.89% and a net margin of 26.92%. The firm had revenue of $204.97 million during the quarter, compared to analyst estimates of $206.45 million. During the same quarter in the prior year, the company earned $1.09 EPS. The business’s revenue was up 12.8% compared to the same quarter last year. As a group, equities analysts expect that ABIOMED, Inc. will post 4.32 earnings per share for the current fiscal year.

ABIOMED Company Profile

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Further Reading: Determine Your Level of Risk Tolerance

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.